In a new pharmaphorum podcast, web editor Nicole Raleigh was joined by Rob DiCicco, vice president of portfolio management at ...

This breakthrough has accelerated peptide drug development across multiple therapeutic areas, including cardiovascular ...

A patient advocacy group in the UK is calling for changes to the decade-old meningitis vaccination programme, after an ...

NYSE-listed Alto Neuroscience has raised $120 million in a private placement that will be used to advance its recently ...

Sales of Voxzogo for achondroplasia grew more than a quarter in 2025 to reach $927 million, making it BioMarin's biggest ...

Roche has ramped up its investment in NVIDIA's AI chips, launching an upscaled hybrid-cloud AI factory that it believes is ...

A federal judge has pushed back against attempts by HHS Secretary Robert F Kennedy Jr to overhaul immunisation policy in the ...

A regimen based on Incyte's PD-1 inhibitor Zynyz and chemotherapy has become the first systemic treatment to be approved in the EU for advanced squamous cell carcinoma of the anal canal (SCAC). Zynyz ...

The consequences of the US-Israel war in Iran have spilled over into the medtech sector, with a cyberattack launched against prominent US company Stryker. An Iranian hacker group has claimed ...

Friday the 13th has turned into a horror story for Australian biotech Immutep, whose share price collapsed after it abandoned a pivotal trial of its lead drug. Immutep's ASX-listed stock fell more ...

Evotec's unit in Abingdon, UK, is one of four locations set to close in project Horizon. Evotec has announced the next phase of its company overhaul, dubbed Horizon, that will see 800 people lose ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in a phase 3 trial, although the drugmaker thinks it has seen signs of ...